Tandem Diabetes Care, Inc. ($TNDM) Stock Forecast: Down 5.4% Today

What is Tandem Diabetes Care, Inc.?

Tandem Diabetes Care (TNDM) is a company specializing in innovative insulin delivery systems, focusing on improving the management of diabetes. Today, the stock experienced a significant bearish movement.

Why is Tandem Diabetes Care, Inc. going down?

TNDM stock is down 5.4% on Jun 8, 2026 16:50

• The bearish movement in TNDM stock could be attributed to a reaction by investors to recent CE mark approvals in the EU for expanded indications of its insulin pumps.
• Despite the news of expanded clearances for Tandem's insulin pumps, the market may have already priced in these developments, leading to profit-taking by traders.
• The initial market response to the expanded indications might have subsided as investors reevaluated the potential impact on Tandem's revenue and market share in the highly competitive diabetes management sector.

TNDM Price Chart

TNDM Technical Analysis

TNDM News

Tandem insulin pumps cleared in EU for expanded indications

This article announces that Tandem Diabetes Care has received expanded indications in the EU for its t:slim X2 insulin pump with Control-IQ technology and t:slim X2 pump with Basal-IQ technology, including younger users and integrated continuous glucose monitoring. The expanded clearances allow for treatment of Type 1 diabetes in patients as young as two years old across the EU. These developments build on previous CE mark approvals for both systems.

https://www.msn.com/en-us/health/other/tandem-insulin-pumps-cleared-in-eu-for-expanded-indications/ar-AA24Uygd

Tandem Diabetes’ Insulin Pumps Win EU Nods for T2D, T1D in Pregnancy

Tandem Diabetes Care has received CE mark approval in Europe for its t:slim X2 and Tandem Mobi insulin pumps using Control-IQ+ AID technology. This expanded indication allows their use for people with type 1 diabetes during pregnancy and adults with type 2 diabetes. The approval for type 1 diabetes in pregnancy is based on the CIRCUIT trial, showing improved time in glucose target range, while the type 2 diabetes approval stems from the 2IQP trial, which demonstrated significant A1C reduction.

https://www.mpo-mag.com/breaking-news/tandem-diabetes-insulin-pumps-win-eu-nods-for-t2d-t1d-in-pregnancy/

Tandem insulin pumps cleared in EU for expanded indications

Tandem Diabetes Care has received CE mark approval in the European Union for expanded indications for its t:slim X2 and Tandem Mobi automated insulin delivery systems. This approval will allow for broader use of these insulin pumps for managing diabetes within the EU.

https://seekingalpha.com/news/4601055-tandem-insulin-pumps-cleared-eu-expanded-label

Tandem Diabetes receives CE mark for expanded insulin pump uses

Tandem Diabetes Care, Inc. received CE mark approval to expand the indications for its automated insulin delivery systems in Europe, now including use for type 1 diabetes during pregnancy and for adults with type 2 diabetes. This expansion covers its t:slim X2 and Tandem Mobi insulin delivery systems, which use Control-IQ+ technology. The company's stock jumped following the announcement, reflecting positive market response to the increased addressable market and strong financial performance insights.

https://www.investing.com/news/company-news/tandem-diabetes-receives-ce-mark-for-expanded-insulin-pump-uses-93CH-4728553

Tandem Diabetes Care Automated Insulin Delivery Systems Receive CE Mark for Type 2 Diabetes and Type 1 Diabetes During Pregnancy

Tandem Diabetes Care has received CE mark approval for its t:slim X2 and Tandem Mobi insulin delivery systems, which utilize Control-IQ+ AID technology, for expanded indications in Europe. These systems are now approved for use by individuals with type 1 diabetes during pregnancy and adults with type 2 diabetes. This expansion is supported by strong clinical evidence from the CIRCUIT trial for type 1 diabetes in pregnancy and the 2IQP trial for type 2 diabetes, demonstrating improved glycemic control and safety.

https://www.businesswire.com/news/home/20260605572579/en/Tandem-Diabetes-Care-Automated-Insulin-Delivery-Systems-Receive-CE-Mark-for-Type-2-Diabetes-and-Type-1-Diabetes-During-Pregnancy

Trending Today

Upstart Holdings Inc. ($UPST) Stock Forecast: Up 5.2% Today

Apple Inc. ($AAPL) Stock Forecast: Down 2.3% Today

Coinbase Global Inc. ($COIN) Stock Forecast: Up 5.0% Today

Kohl's Corporation ($KSS) Stock Forecast: Up 5.2% Today

Tandem Diabetes Care, Inc. ($TNDM) Stock Forecast: Down 5.4% Today

Pinterest Inc. Class A ($PINS) Stock Forecast: Up 5.3% Today

Amplitude Inc. ($AMPL) Stock Forecast: Down 5.5% Today

Marathon Digital Holdings Inc. ($MARA) Stock Forecast: Up 5.1% Today

Centene Corporation ($CNC) Stock Forecast: Up 4.4% Today

Novavax Inc. ($NVAX) Stock Forecast: Down 5.3% Today

Tandem Diabetes Care, Inc. Price History

04.05.2026 - TNDM Stock was up 8.9%

• Tandem Diabetes Care (TNDM) experienced a bullish movement today, likely driven by positive investor sentiment and growth prospects indicated by recent strategic business model transitions and international expansion efforts.
• The news of key executives, including the CEO and other officers, receiving significant RSU grants under the 2023 Long-Term Incentive Plan could have also contributed to the bullish momentum, signaling confidence in the company's future performance and aligning leadership interests with shareholder value.
• The reaffirmed 2026 guidance and strong solvency profile further reinforced investor confidence in Tandem's long-term prospects, despite near-term profitability challenges.
• Overall, the combination of growth initiatives, executive incentives, and financial stability likely fueled the bullish movement in TNDM stock today.

04.05.2026 - TNDM Stock was up 8.0%

• The positive sentiment surrounding Tandem Diabetes Care's (TNDM) leadership team receiving significant Restricted Stock Units (RSUs) under the 2023 Long-Term Incentive Plan could have contributed to the bullish movement in the stock market today. This act of granting equity awards may indicate confidence in the company's future performance.
• Granting RSUs to key executives, including the CEO, EVP, and CFO, helps align their interests with long-term shareholder value. This alignment might enhance investor confidence in TNDM's strategic direction and growth opportunities.
• Despite recent share price fluctuations and concerns over TNDM's valuation, the disclosure of equity awards to top management could potentially reassure investors about the company's dedication to driving sustainable growth and profitability, likely influencing the positive market movement.

01.05.2026 - TNDM Stock was down 6.5%

• TNDM stock saw a decrease today, possibly due to Citigroup maintaining a Neutral rating on the company but revising the price target downward from $22.00 to $17.00. This adjustment, influenced by market changes and competition, may have unsettled investors.
• GuruFocus suggested that TNDM is undervalued by 43.8% based on its GF Value™ and added a "Possible Value Trap" designation, along with insider selling. These factors might have contributed to the negative sentiment towards the stock.
• Despite the undervaluation, investors are advised to be cautious, which could have prompted some to sell their shares, further impacting the decline in TNDM stock today.

29.04.2026 - TNDM Stock was up 18.4%

• Maintaining a Neutral rating but lowering the price target could have initially caused some uncertainty, but the undervaluation by 43.8% may have sparked investor interest.
• The approval of an expanded long-term incentive plan and progress on new insulin pump launches indicate the company's commitment to long-term growth, potentially boosting investor confidence.
• The equity compensation activities of key figures like Chair Emeritus Dick Allen and Director Sandra Beaver, receiving RSUs and aligning their interests with shareholders, could have contributed to a positive outlook for the company.
• Overall, the combination of strategic growth initiatives, undervaluation, and alignment of interests through equity compensation may have driven the strong bullish movement in TNDM's stock today.

05.05.2026 - TNDM Stock was up 5.3%

• A recent insider trading activity involving the Chief Strategy Officer gifting shares to a family trust may have indicated confidence in the company's future outlook, contributing to favorable market sentiment.
• Tandem Diabetes Care's strategic shift in business model, efforts towards international expansion, and upcoming product launches are viewed as significant drivers for future revenue growth, appealing to investors.
• The recent allocation of Restricted Stock Units to the Chief Operating Officer may have also bolstered confidence in the leadership team's capabilities to propel the company's growth, further enhancing investor confidence.
• Despite concerns outlined in the valuation analysis, including competition and execution challenges, the overall positive developments and strategic initiatives by Tandem Diabetes Care appear to have outweighed these risks for investors, leading to the bullish market movement.

13.04.2026 - TNDM Stock was down 5.5%

• Tandem Diabetes Care (TNDM) stock saw a significant decrease of 14.14% in after-hours trading, despite achieving record revenue and surpassing EPS estimates in Q1 2026.
• The initiation of coverage by Benchmark with a 'Hold' rating, showcasing varied analyst views and possible volatility, may have led to investor uncertainty.
• A research report by StockStory assigning an "Underperform" rating due to worries regarding modest sales growth and high valuation in comparison to business quality could have impacted the bearish trend.
• Despite making positive strides operationally and confirming full-year guidance, investor apprehensions about valuation, expense control, and long-term trends might have influenced the stock's decline.

15.04.2026 - TNDM Stock was down 10.5%

• Tandem Diabetes Care (TNDM) posted a narrower loss, surpassed revenue expectations, and notably expanded its gross margin. Interestingly, the stock saw a significant 23.6% decline post-earnings, sparking speculation on potential factors:
• Market sentiment may have soured over doubts about the company's sustainability of growth or concerns regarding future sales performance, despite confirming its annual sales outlook.
• The 'Hold' rating from Benchmark upon initiating coverage, suggesting a balanced valuation and potential volatility, could have contributed to investor wariness, leading to downward stock pressure.
• Despite technical signals indicating a possible trend shift, a recent 26.5% decrease in TNDM's share price across four weeks might have influenced investor sentiment, prompting profit-taking and sell-offs.
• Ultimately, a blend of market sentiment, analyst evaluations, and technical indicators likely converged to shape a pessimistic short-term outlook for Tandem Diabetes Care (TNDM), contrasting with positive financial results and growth potential in the long run.

27.04.2026 - TNDM Stock was down 5.0%

• Shareholders' approval of an expanded long-term incentive plan and recent equity compensation activities involving key individuals at Tandem Diabetes Care could have raised concerns among investors regarding the company's long-term growth outlook and talent retention.
• The company's issuance of stock-based compensation and the granting of restricted stock units (RSUs) to directors may have sparked uncertainties about TNDM's financial stability and strategic path, leading to a lack of confidence in its future performance.
• Despite advancements in new insulin pump releases and optimistic revenue and earnings growth forecasts by 2029, the intensifying competition and possible margin pressures mentioned in recent updates might have contributed to TNDM's bearish market activity.
• The emphasis on aligning management and shareholder objectives for prolonged growth, while crucial, may have also highlighted existing hurdles and uncertainties within the company, further influencing investor sentiment and prompting the downward movement in TNDM's stock price.

02.05.2026 - TNDM Stock was down 5.4%

• An upgrade of Tandem Diabetes Care to "Overweight" with an increased price target to $27 did not prevent the bearish movement, indicating other market factors at play.
• Historical challenges, such as a significant decline in stock price over the past year and low return on equity, likely contributed to the bearish trend.
• The filing of a shelf registration for an ESOP-related offering and changes in director removal rules may have raised concerns among investors.
• Despite the recent surge in stock price and positive sales data, the overall market sentiment towards Tandem Diabetes Care remains cautious, emphasizing the need for a thorough evaluation of the company's long-term prospects.

20.04.2026 - TNDM Stock was up 5.1%

• Tandem Diabetes Care (TNDM) experienced a bullish market movement today, likely driven by positive sentiment and confidence in the company's leadership and growth prospects.
• The routine equity compensation activities reported by TNDM's legal chief, CTO, and EVP may have instilled trust and stability among investors, showcasing commitment and alignment of interests with shareholders.
• The focus on the "Silver Economy" and the healthcare sector's growth opportunities, including TNDM's innovative initiatives, could have further boosted investor optimism and contributed to the stock's upward momentum.
• Despite a price target cut by B of A Securities, the overall positive industry outlook and company-specific developments seem to have outweighed this factor, leading to the bullish movement in TNDM's stock price.

12.04.2026 - TNDM Stock was up 5.0%

• Tandem Diabetes Care reported impressive Q1 2026 earnings, beating estimates with a revenue of $247.22 million and an EPS of -$0.30, showing a 5.46% year-over-year increase. This positive financial performance likely fueled investor confidence and contributed to the bullish movement in the stock.
• Despite the record sales and positive operational progress, the stock initially dropped by 14.14% in after-hours trading, possibly due to investor concerns. However, the company's reaffirmation of its full-year guidance and growth expectations from new technologies and business models could have reassured investors, leading to the bullish trend.
• Truist Financial maintaining a Buy rating on Tandem Diabetes Care, albeit with a slightly reduced target price, indicates continued optimism in the company's future prospects. This vote of confidence might have further supported the bullish momentum in the stock.
• Tandem Diabetes Care's strategic initiatives, such as expanding internationally, launching new products like Control-IQ+ for pregnant women, and addressing supply chain challenges, demonstrate a proactive approach to growth. These factors, combined with the positive earnings report, likely contributed to the bullish market movement of the stock.

08.05.2026 - TNDM Stock was down 5.4%

• The bearish movement in TNDM stock could be attributed to a reaction by investors to recent CE mark approvals in the EU for expanded indications of its insulin pumps.
• Despite the news of expanded clearances for Tandem's insulin pumps, the market may have already priced in these developments, leading to profit-taking by traders.
• The initial market response to the expanded indications might have subsided as investors reevaluated the potential impact on Tandem's revenue and market share in the highly competitive diabetes management sector.